MAPT and Alzheimer disease: Studies (Barthelemy et al., 2020; Suarez-Calvet et al., 2020) showed that p-Tau181 levels were significantly increased in preclinical AD, when only subtle signs of Aβ pathology can be detected or as early as two decades before the development of aggregated tau pathology.